NCT06300723View on ClinicalTrials.gov

Clinical Study of BRL-101 in Severe SCD

NAEnrolling by invitationINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

March 20, 2026

Study Completion Date

June 15, 2026

Conditions
Sickle Cell Disease
Interventions
DRUG

BRL-101

CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.

Trial Locations (1)

530021

First Affiliated Hospital of Guangxi Medical University, Nanning

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT06300723 - Clinical Study of BRL-101 in Severe SCD | Biotech Hunter | Biotech Hunter